Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024

Company Overview - Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs [3] - The company has proprietary ADC platforms, including Dolasynthen and Immunosynthen, which are generating a pipeline of product candidates [3] Pipeline and Product Candidates - Mersana's pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2) [3] Upcoming Financial Results - Mersana will provide business updates and report its financial results for the second quarter ended June 30, 2024, on August 13, 2024 [1] - A conference call and webcast will be held at 8:00 a.m. Eastern Time on the same day [1]